Story perspectives

Breakthrough Gene Therapies Show Promise for Canavan Disease

9/18/2025

50 8

Summary

Story summary

Canavan disease (CD) is a severe genetic disorder caused by mutations in the ASPA gene, resulting in neurological decline and early death.
A Phase I/II trial of MYR-101, a gene therapy for oligodendrocytes, showed significant improvements in white matter and developmental scores in eight children.
The therapy achieved over an 80% reduction in CSF NAA concentration and increased brain myelination.
Capsida's SYNRGY trial for gene therapy CAP-002 was paused following a patient death, with the cause under investigation.
Fujifilm introduced a new cell culture medium to enhance gene therapy production, potentially reshaping approaches for demyelinating conditions.

1 of 1

Story summary

Canavan disease (CD) is a severe genetic disorder caused by mutations in the ASPA gene, resulting in neurological decline and early death.
A Phase I/II trial of MYR-101, a gene therapy for oligodendrocytes, showed significant improvements in white matter and developmental scores in eight children.
The therapy achieved over an 80% reduction in CSF NAA concentration and increased brain myelination.
Capsida's SYNRGY trial for gene therapy CAP-002 was paused following a patient death, with the cause under investigation.
Fujifilm introduced a new cell culture medium to enhance gene therapy production, potentially reshaping approaches for demyelinating conditions.